Results 71 to 80 of about 17,802 (177)
PLoS ONE, 2020 PurposeThe objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice.MethodsThis observational, retrospective ...
Francisco Barrero +12 more
doaj +1 more source
Health Literacy and Unmet Needs in Patients With Multiple Sclerosis: A Cross‐Sectional Study
Journal of Clinical Nursing, Volume 35, Issue 11, Page 4816-4827, November 2026.ABSTRACT Aims To identify a correlation between unmet needs and HL levels in people with Multiple Sclerosis (pwMS) and to evaluate how sociodemographic characteristics influence HL levels and unmet needs. Design A cross‐sectional study. Methods The study was conducted using a questionnaire including the HLS19‐Q12 to assess HL and the Long‐term Unmet ...
Francesco Pastore +6 more
wiley +1 more source
Toxicidad hepática por fingolimod
, 2023 We present the case of a patient with a history of multiple sclerosis under chronic fingolimod treatment who presents abdominal pain associated with jaundice associated with transaminitis that by biopsy is associated with late hepatotoxicity due to ...
Arenas Peña, Gabriel José +4 more
core
Neurología (English Edition), 2014 Introduction: At present, there is a lack of economic assessments of second-line treatments for relapsing-recurring multiple sclerosis. The aim of this study was to compare the efficiency between fingolimod and natalizumab in Spain.
C. Crespo +4 more
doaj +1 more source
International Journal of Cancer, Volume 159, Issue 8, Page 1857-1872, 15 October 2026.ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang +10 more
wiley +1 more source
Lymphocyte recovery after fingolimod discontinuation in patients with MS.
, 2020 OBJECTIVE To investigate the dynamics of immune cells recovery after treatment discontinuation of fingolimod in real-life clinical practice, we analyzed the course of lymphocyte reconstitution and its potential influencing factors in patients with ...
Kuhle J, Nagy S, Derfuss T
core +1 more source
The impact of fingolimod on Treg function in brain ischaemia
, 2023 Fingolimod has generally shown neuroprotective effects in stroke models. Here, we tested the hypothesis that fingolimod modulates T-cell cytokine production towards a regulatory phenotype.
Waeber, Christian +7 more
core +1 more source
Fingolimod after natalizumab and the risk of short-term relapse
, 2014 OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to ...
C Boz (13311711) +19 more
core +2 more sources
BMC MicrobiologyBackground The urgent need for new antibacterial drugs has driven interest in repurposing therapies to combat Gram-positive biofilms and persisters.
Yongpeng Shang +5 more
doaj +1 more source
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, Volume 13, Issue 10, Page 2017-2026, October 2026.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source